Darunavir (Prezista®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000457
English
Authors' recommendations:
Darunavir (Prezista®) should be recommended within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated adults who have failed more than one regimen containing a protease inhibitor (PI), and where resistance profiling suggests it is appropriate.
Use should be in accordance with the British HIV Association (BHIVA) guidance.
Darunavir (Prezista®) is not presently recommended for shared care.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=85963&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Sulfonamides
- HIV Protease Inhibitors
- HIV
- HIV Infections
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.